HIGHFIELD ¹H AND ¹³C NMR OF 5-OXYGENATED CHOLESTANE-6-OXIME DERIVATIVES

Helmut Duddeck^a*, Jadwiga Frelek^b, Wojciech J. Szczepek^b and Wladislaw J. Rodewald^b.


^aRuhr University Bochum, Faculty of Chemistry, P.O.B. 102148, D-4630 Bochum 1, West Germany; ^bUniversity of Warsaw, Department of Chemistry, Pasteura 1, PL-02-093 Warsaw, Poland.

(Received April 27,1987)

ABSTRACT: The oxime groups in twelve title compounds were found to be in the E-configuration by determination of the chemical shifts of the ring B carbons. For some compounds all ¹H and ¹³C NMR signals were assigned by using two-dimensional correlated NMR methods.

INTRODUCTION

In continuation of CD investigations of simple hydrazones a



Highfield ¹H and ¹³C NMR

series of steroidal oximes and acetoximines substituted at rings A and B with different stereochemistry and substitution pattern have been synthesized from the corresponding ketones using conventional methods (1). For the CD interpretations, of course, a sound knowledge of the oxime configuration was mandatory.

RESULTS AND DISCUSSION

The easiest way to establish the stereochemistry of the 6-oxime groups in the cholestanes 1-12 is to compare the ¹³C chemical shifts of C-7 in these compounds with those of corresponding ketones, since in the E-orientation of the hydroxyl group the C-7 signal should be shielded much more significantly compared to the keto derivative than in the Z-configuration (2,3). Moreover, in the E-configuration C-8 should suffer a 1-2 ppm shielding whereas its signal shift should be very similar to that of the ketone if the hydroxyl group

is in Z-grientation.

A 13 C signal assignment of steroids can be achieved by comparing the spectral data with those of documented spectra with similar structure. The 13 C NMR data of a large number of cholestanes have been collected in reviews published by Blunt and stothers and by other authors (4). This method, however, is purely empirical and therefore we decided to confirm such assignments by a more rigorous method using two-dimensional homo- (1 H- 1 H) and heteronuclear (1 H- 13 C) correlated NMR techniques (COSY) which afford unambiguous atom connectivities (5). Such application has been described by us recently in a paper on the 1 H and 13 C NMR spectroscopy of corticosteroids (6).

In the past, proton signal assignments of steroids were restricted to high-frequency signals which are not overlapped by others or to sharp methyl peaks (7). Hassignments of signals in highly crowded spectral areas of steroids became possible only after the availability of highfield spectrometers and two-dimensional techniques (6,8). To the best of our knowledge, however, no such 1H NMR investigation of cholestane derivatives has been described. In fact, such spectra are particularly difficult to interpret because signal overlap in the region of $\delta = 1-2$ is extremely severe due to the many hydrogens in the aliphatic C, side chain. In four instances (1,4,6 and 10) we carried out the full 1H signal assignments of the cholestane 6-oxime compounds and the chemical shifts are listed in Table 1. For all other compounds we can find overlapped signals which apparently correspond to those of the four but their identity has not been proven. In such cases only the chemical shifts of the prominent peaks are noted in the Experimental Part.

For the compounds 1,4,6 and 10 the application of Homo- and heteronuclear COSY spectroscopy enabled reliable ¹³C signal assignments (Tables 2 and 3) except in a few cases where the carbon resonances were too close to be resolved in the two-dimensional experiment and the resonances of the attached protons could not be identified unambiguously because they were also very near to each other. In such cases we refrained from further painstaking experiments because this was not necessary for our main goal, namely

to establish the oxime configuration. The $^{13}\mathrm{C}$ assignments of all other compounds were achieved using analogy arguments and contain also a few minor ambiguities.

Table 1: ¹H chemical shifts of some cholestane derivatives^a

aIn ppm, relative to the solvent peak (CDCl₃: δ=7.24), at 400.1 MHz. For the other compounds see Experimental Part. bStereochemical notation only if proven unequivocally. CMay be interchanged. Could not be identified accurately.

The C-7 chemical shifts are $\delta=25-26$ for the 6-oximes (x³=0H). A comparison of these values with corresponding chemical shifts in cholestan-6-ones (4a) reveals that downfield shifts of ca 18-19 ppm occur if the keto oxygen is substituted by NOH. This clearly proves that the oxime hydroxy group is E-oriented since in Z-configuration chemical shifts in the range of $\delta=35-36$ would be expected (2,3). Moreover, the C-8 atoms suffer a 2-3 ppm shielding upon the same molecular transformation again indicating E-

configuration (2,3) (see above). In the spectra of the acetoximines the C-7 chemical shifts are ca 2 ppm higher.

Table 2: ^{13}C chemical shifts of the 5α -cholestane oximes 3

0.100					-		_	
C-No.	1	2	3	4	5	6	7	8
1	30.7	25.8b	25.8	29.7	29.5	29.8	29.8	31.2
2	20.6b	24.8b	24.8	26.5	26.4	26.5	26.4	32.0
3	20.2b	70.3	70.2	72.0	70.5	70.3	69.8	56.7
4	29.0	31.7	31.7	33.5	34.2	27.8	27.8	39.9
- 5	75.7	75.8	76.4	76.7	77.4	81.8	82.3	77.4
6	162.7	161.3	168.4 ^b	62.9	169.6	160.3	167.8	161.8
4 5 6 7 8	25.3	25.0 ^b	27.1	24.9	27.3	25.6	27.8	25.1
8	34.7		35.3	34.8	35.3	35.2	35.6	34.6
9	45.2	44.9	44.8	44.4	44.4	44.3	44.1	44.7
10	41.6		42.5	41.1	41.5	42.2	42.6	40.9
11	21.0	21.0	20.9 39.4 ^b	21.3	21.3 39.4 ^b	21.3 39.5 ^b	21.2 39.4b	21.3
12	39.8	39.8b	39.45	39.7b	39.45	39.50	39.40	39.7b
13	43.0	43.0	43.0	43.0 56.1 ^b	43.0 56.1b	43.0	43.0	43.0
14	56.4	56.3b			56.10	56.2b	56.0	56.2b
15	24.0	24.0	23.9	24.0	24.0		24.0	24.0
16	28.2	28.2	28.1	28.2	28.1	28.2	28.0	28.2
17	56.1	56.2b	56.1	56.0b	56.0 ^b	56.1 ^b	56.0	56.1b
18	12.1	12.1	12.0	12.1	12.0	12.1	12.0	12.1
19	14.3	14.1	14.0	14.2	14.2	14.6	14.6	14.4
20	35.8	35.8	35.7	35.7	35.7	35.7	35.6	35.7
21	13.6	18.6	18.6	18.6	18.6	18.6	18.5	18.6
22	36.1	36.1	36.0	36.1	36.1	36.1	36.0	36.1
23	23.8	23.9 39.5 ^b	23.8 39.6 ^b	23.8 39.5 ^b	23.9 39.6b	23.8	23.7	23.8
24	39.5	39.5	39.6			39.7b	39.5b	39.5 ^b
25 26	28.0	28.0	27.9	28.0	27.7	28.0	27.9	28.0
27	22.5	22.5	22.5	22.6	22.5	22.5	22.5	22.5
	22.8	22.8	22.7	22.8	22.8	22.8	22.7	22.8
AC		21.4	21.4	21.6	21.4	21.4	21.3	
		169.1	169.6b	172 0	17.5 170.9	170.7	19.8	
		102.1	168.4b	172.0	169.3	170.7	170.5	
CYTI			T00 * 4		T03.7	10 E	169.2	
CCH ₃						49.5	49.8	

 $^{\rm a}{\rm In}$ ppm, relative to the central peak of the solvent (CDCl3: $\delta\!\!=\!\!77.0)$, at 100.6 MHz. $^{\rm b}{\rm may}$ be interchanged.

For the interpretation of various substitutent effects on carbon signals and chemical shift alterations by A/B ring junction changes, the reader is referred to review articles elsewhere (4).

It is interesting to observe the signals of the equatorial H-7 β appearing at δ = 2.9-3.25 in all compounds. In most cases it is a doublet of doublet due to the couplings $J_{7\alpha}$, $_{7}\beta$ = 13-14 Hz and $J_{7\beta}$, = 4-5Hz (cf. Fig. 1, left). For 6 and 10, however, they are different (cf. Fig. 1, right). Here the signals represent X-parts

Table 3: 13C Chemical shifts of 5 β-cholestane acetoximes^a

C-No.	9	10	11	12
1	25.3	25.1	26.1 ^b 24.4 68.2 28.7 84.3 155.0	26.0
2	24.4	24.4		24.4
3	69.0	68.1		67.8
4	36.4	36.5		29.1
5	75.6	76.1		84.0
6	160.3	168.3		170.0
7	26.3	28.7	26.8 ^b	28.0
8	34.6	35.0	35.2	35.9
9	42.7	42.5	42.9	43.0
10	42.1	43.2	42.5	43.6
11	21.4	21.3	21.4	21.4
12	39.4 ^b	39.5	39.4 ^b	39.4 ^b
13	42.8	42.9	42.9	43.0
14	56.8	56.6	56.6	56.5
15	24.0	24.0	24.0	24.1
16	28.1	28.0	28.1	28.0
17	56.0	56.0	56.0	56.0
18	11.9	11.9	12.0	12.0
19	16.3	16.8	16.8	16.7
20	35.6	35.6	35.6	35.6
21	18.6	18.6	18.6	18.6
22	36.1	36.0	36.0	36.0
23	23.7	23.7	23.7	23.7
24	39.6 ^b	39.5	39.6	39.5 ^b
25	28.0	27.9	27.9	28.0
26 27 Ac	22.5 22.8 21.6	22.5 22.7 21.5 19.7	22.5 ^b 22.7 21.3 22.4 ^b	22.5 ^b 22.8 20.2 21.3 22.3 ^b
	170.9	170.7 169.0 ^b	170.4 170.1	169.8 ^b 171.1

^aIn ppm, relative to the central peak of the solvent (CDCl₃: ô =77.0), at 100.6 MHz. ^bMay be interchanged.

of ABX spectra because the signals of the two coupling partners H-7 α and H-8 are nearly coinciding. Each of the large center lines of these signals consist of two accidentally overlapping lines with a distance of ca 9 Hz. This is, indeed, the sum of the two coupling constants since the geminal coupling constant $(J_{7}\alpha,r_{7}\beta)$ is negative and the vicinal $(J_{7}\beta,r_{8})$ positive. The small outer lines are due to the so called "virtual" coupling (combination lines) (9). The reason for the overlap of the singals of E-7 α and H-8 is different for both molecules:



Fig. 1: H-7 β signals of 9 (left) and 10 (right)

The H-7 β atoms resonate uniformly at δ =2.9-3.1 in the 5 α - and δ = 3.1-3.25 in the 5 β -cholestanes. Likewise, the H-8 chemical shifts (δ = 1.4-1.5) are rather independent of the substitution pattern. The shielding of H-7 α , however, reacts sensitively on the nature of nearby substituents. In the dihydroxy compound 4 it appears at δ = 1.74, remote enough from the H-8 signal to produce a first-order AMX spectrum. Acetylation of the oxime OH (4-5) further enhances the distance (δ [H-7 α] = 2.04). Methylation of the hydroxyl group at C-5, however, (4-6) causes a 0.3 ppm shielding of H-7 α so that this signal and that of H-8 are nearly isochronous. In contrast to the acetoximine 5 the chemical shifts of H-7 α and H-8 in 10 are nearly indistinguishable even at 400 MHz again giving rise to an ABX spectrum. In 9, however, this is different because the 0.3 ppm deshielding exerted by the acetyl group is missing.

EXPERIMENTAL

The melting points were determined on a Boetius micro-melting point apparatus and are uncorrected. Column chromatography was performed on silica gel (Kieselgel 60, 70-230 mesh, Merck). Optical rotations were measured on a Perkin-Elmer 241 polarimeter in chloroform solutions and concentrations are expressed in mg/cm³. The infrared spectra were recorded on a UR-20 spectrophotometer in KBr. Mass spectra were taken on a LKB 2031 or a Varian MAT CH-4 spectrometer. H NMR spectra were taken at 100 MHz on a Bruker WP-100SY or at 400.1 MHz on a Bruker AM-400 and 13C NMR spectra on a Bruker AM-400 spectrometer in CDCl₃ solutions under normal conditions. For the two-dimensional spectra (H-1H and H-13C correlated) standard Bruker software and parameter sets were used as described earlier (10).

Synthesis of the oximes 1, 2, 4, 6, 8, 9 and 11

To a solution of the corresponding hydroxyketone in pyridine an excess of hydroxylamine hydrochloride was added and the reaction mixture was left at room temperature for a definite time. Then the excess solvent was evaporated under reduced pressure and the residue was treated with dilute hydrochloric acid. The product was extracted with benzene and the organic layer was washed with water, aqueous NaHCO3 solution and finally with water. The extract was dried over anhydrous Na2SO4, filtered and the solvent removed under reduced pressure giving a crude product which was purified by filtration through alumina and then by crystallization from the indicated solvent. The results of these reactions are summarized below.

Hydroxyketone [q]	Pyridine [cm ³]	NH ₂ OH.HCl	Reaction Time [days]	Product [q]	Yield [%]
2.0	50	2	3	1:1.95	97
3.0	30	3	1	2:2.80	90
2.0	20	2	3	4:1.50	73
3.0	30	4	9	6:2.90	94
5.0	50	5	2	8:4.00	77
8.0	80	8	3	9:5.00	61
4.0	80	4	4	11:3.50	83

The isolated products gave the following data:

6E-Hydroximino-5a-cholestan-5-ol (1) (11,12) M.p. $192-195^{\circ}$ C (Et₂O-hexane); [a]_D-49.6 (c, 10.8); IR, cm⁻¹: 3380, 1660, 1166, 940, 912, 879; MS, m/z (relative intensity): 417 (M⁺, 18.6), 400 (M⁺-OH, 100), 357 (M⁺ H₂O-CH₂CO, 49.4), 112 (C₇H₁₂O⁺, 51.4); Anal.: calcd. for C₂₇H₄₇NO₂: C, 77.64; H, 11.34; N, 3.35; found: C, 77.5; H, 11.22; N, 3.30.

6E-Hydroximino- 5α -cholestan- 3α , 5-diol 3-acetate (2) M.p. 223-224.5°C (MeOH); [α] 5-8.6 (c, 14.6); IR, cm⁻¹: 3572, 3456, 1729, 1275, 1030, 942, 916; IH NMR, δ (CBCl3): 9.7 (NGH), 5.25 (H-3 B), 3.33 (C⁵-OH), 3.09 (H-78), 2.16 (H-4 α), 2.03 (Ac), 0.88 (H-21), 0.84 (H-26/H-27), 0.78 (H-19), 0.63 (H-18); MS, m/z (relative intensity): 475 (M⁺, 25.0), 458 (M⁺-OH, 39.7); 415 (M⁺-AcOH, 14.7), 398 (M⁺-OH-AcOH, 33.8), 388 (M⁺-CO-AcO, 17.6), 387 (M⁺-CO-AcOH, 17.6), 110 (C₇H₁₀O⁺, 40.2), 43 (100); Anal.: calcd. for C₂₉H₄₉NO₄: C, 73.22; H, 10.38; N, 2.94; found: C, 73.12; H, 10.19; N, 2.79.

6E-Hydroximino-5 α -cholestan-3 β , 5-diol 3-acetate (4) (12-14) M.p. 135-136.5/167-168 $^{\circ}$ C (EtOH); [α]_D -96 (c, 10.5); IR, cm⁻¹: 3466, 1724, 1652, 1274, 1050, 947, 918; MS, m/z (relative intensity): 475 (M⁺, 25.8), 458 (M⁺-OH, 43.3), 398 (M⁺-OH-AcOH, 24.2), 110 (C₇H₁₀O⁺, 95), 68 (100); Anal. calcd. for C₂₉H₄₉NO₄: C, 73.22; H, 10.38; N, 2.94; found: C, 73.06; H, 10.21; N, 2.83.

Highfield 1H and 13C NMR

6E-Hydroximino-5-methoxy-5 $^{\alpha}$ -cholestan-3 $^{\beta}$ -ol 3-acetate (6) (15) M.p. 230-232 $^{\circ}$ C (MeCH); [$_{\alpha}$] _ -68.6 (c, 10.5); IR, cm $^{-1}$: 3458, 1718, 1664, 1274, 1067, 946, 918; MS, m/z (relative intensity): 489 (M $^{+}$, 23.4), 472 (M $^{+}$ -OH, 20.9), 412 (M $^{+}$ -OH-AcOH, 37.5), 123 (C₈H₁₁O $^{+}$, 100); Anal.: calcd. for C₃₀H₅₁NO₄: C, 73.58; H, 10.50; N, 2.86; found: C, 73.32; H, 10.41; N, 2.76.

 3β -Chloro-6E-hydroximino-5 α -cholestan-5-ol (8) (13,16,17) M.p. 193-195 C (Et_2O-hexane); [α] D -49.9 (c,9.1); IR, cm $^{-1}$: 3480, 1660, 943, 913, 764, 693; 1 H NMR, δ (CDCl_3): 9.75 (NOH), 4.28 (H-3 α), 3.12 (H-7 β), 0.88 (H-21), 0.85 (H-19), 0.84 (H-26/H-27), 0.62 (H-18); MS, m/z (relative intensity): 451 (M $^{+}$, 29.2), 434 (M $^{+}$ -OH, 69.2), 388 (M $^{+}$ -CO-Cl, 54.2), 146 (C₇H₁₁ClO $^{+}$, 44.2), 110 (C₇H₁₀OH $^{+}$, 78.3), 68 (85.9), 43 (100); Anal. calcd. for C₂₇H₄₆ClNO₂: C, 71.73; H, 10.18; N, 3.10; found: C, 71.59; H, 10.10; N, 2.95.

6E-Eydroximino-5 β -cholestan-3 β , 5-diol 3-acetate (9) (14) M.p. 182-184.5°C (EtOH); [α]_D +7.4 (c, 14.6); IR, cm⁻¹: 3420, 1733, 1715, 1670, 1243, 1170, 1052, 1020, 923; 1 H NMR, δ (CDCl₃): 9.5 (NOH, broad), 5.08 (H-3 α), 3.7 (C⁵-OH), 3.25 (H-7 β), 2.19 (H-4 β), 2.04 (Ac), 0.88 (H-21), 0.84/0.83 (H-26/H-27), 0.81 (H-19), 0.62 (H-18); MS, m/z (relative intensity): 338 (M⁺-AcO-CO, 100), 387 (M⁺-AcO+CO, 68.7); 110 (C₇H₁₀O⁺, 52.5); Anal.: calcd. for C₂9H₄9NO₄: C, 73.22; H, 10.38; N, 2.94; found: C, 72.98; H, 10.17; N, 2.86.

6E-Hydroximino-5 $^{\beta}$ -cholestan-3 $^{\beta}$, 5-diol 3, 5-diacetate (11) M.p. 216-219 $^{\circ}$ C (EtOH); [$^{\alpha}$]_D -34.3 (c, 11.4); IR, cm⁻¹: 3440, 1747, 1730, 1657, 1280, 1245, 1100, 1050, 1022, 948, 926, 903; 1 H NMR, $^{\delta}$ (CDCl₃): 9.9 (NOH), 5.15 (H-3 $^{\alpha}$), 3.3-3.2 (C⁵-OH), 3.25 (H-7 $^{\beta}$), 2.20 (H-4 $^{\beta}$), 2.04/1.96 (2Ac), 0.87 (H-19/H-21), 0.83 (H-26/H-27), 0.62 (H-18); MS, m/z (relative intensity): 457 (M⁺-AcOB, 29.6), 398 (M⁺-AcO-AcOH, 100), 397 (M⁺-2AcOH); Anal. calcu. For C₃₁H₅₁NO₅: C, 71.92; H, 9.93; N, 2.71; found: C, 71.81; H, 9.76; N, 2.68.

Synthesis of the oxime acetates 3, 5, 7, 10 and 12

A mixture of the oxime, pyridine and acetic anhydride was left at room temperature for a definite time. Then the excess solvent was removed under reduced pressure (using a water bath heated to 50°C). The residue was treated with water and then extracted with ether. The organic layer was washed successively with 5% HCl, ag. Na₂CO₃, water and then dried over anhydrous Na₂SO₄. After evaporation of the solvent the residue was chromatographed and fractions of the main product (less polar than the substrate) were collected and evaporated to dryness. The oxime acetate was crystallized by dissolution in ether, addition of hexane or pentane and slow evaporation of the ether at room temperature. The results of these reactions are summarized below:

Oxime [g]	Pyridine [cm ³]	Ac ₂ 0 [cm ³]	Reaction Time [hours]	Product [g]	Yield [%]
2: 0.55	5	1.5	1 .	3: 0.50	77
4: 1.53	30	2	1	5: 1.26	81
6: 0.60	5	2	24	7: 0.60	83
9: 2.50	50	3	72	10: 2.50	92
11:0.27	2	1	24	12: 0.28	97

6E-Acetoximino- 5^{α} -cholestan- 3^{α} ,5-diol 3-acetate (3) M.p. $135-136.5^{\circ}$ C (Et₂O-hexane); [α]_D -54.7 (c, 9.0); IR, cm⁻¹: 3570, 1780, 1740, 1650, 1213, 1028, 940, 871; 1 H NMR, $^{\circ}$: 5.25 (H-3 $^{\circ}$), 3.55 (C⁵-OH), 2.94 (H-7 $^{\circ}$), 2.34 (H-4 $^{\circ}$), 2.14 (NOAc), 2.03 (C³-OAc), 0.87 (H-21), 0.83 (H-26/27), 0.80 (H-19), 0.62 (H-18); MS, m/z (relative intensity): 458 (M⁺-AcO, 3.1), 397 (M⁺-2AcOH, 17.2), 369 (M⁺-2AcOH-CO, 15.3), 110 (C₇H₁O⁺, 100); Anal.: calcd. for C₃₁H₅₁NO₅: C, 71.92; H, 9.93; N, 2.71; found: C, 71.89; H, 9.92; N, 2.61.

6E-Acetoximino-5α -cholestan-3β, 5-diol 3-acetate (5) (12,18) M.p. 156-158°C (Et₂O-hexane); [α]_D -74.3 (c, 9.6); IR, cm⁻¹: 3430, 1777, 1743, 1715, 1648, 1250, 1044, 940, 920; H NMR, δ: 5.02 (H-3α), 2.93 (H-7β), 2.7 (C⁵-OH), 2.14 (NOAc), 1.98 (C³-OAc), 0.88 (H-21), 0.84 (H-19), 0.84/0.83 (H-26/27), 0.62 (H-18); MS, m/z (relative intensity): 458 (M[†]-OAc, 42.0), 397 (M[†]-2AcOH, 42.1), 369 (M[†]-2AcOH-CO, 63.9), 110 (C₇H₁₀O[†], 100); Anal. calcd. for C₃₁H₅₁NO₅: C, 71.92; H, 9.93; N, 2.71, found: C, 71.86; H, 9.81; N, 2.68.

6E-Acetoximino-5-methoxy-5 α -cholestan-3 β -ol 3-acetate (7) M.p. 127-130°C (Et₂O-pentane); [α]_D-62.1 (c, 10.7); IR, cm⁻¹: 1783, 1734, 1647, 1245, 1068, 939, 871; H NMR, δ : 4.82 (H-3 α), 3.08 (OCH₃), 2.92 (H-7 β), 2.13 (NOAc), 1.96 (C³-OAc), 0.86 (H-21), 0.83 (H-19), 0.83/0.82 (H-26/27), 0.62 (H-18); MS, m/z (relative intensity): 531 (M⁺, 0.6), 473 (M⁺-OAc, 56.8), 413 (M⁺-2AcO, 37.6), 412 (M⁺-AcO-AcOH, 100), 123 (C₈H₁₁O⁺, 50.7); Anal.: calcd. for C₃2H₅3NO₅: C, 72.28; H, 10.05; N, 2.63; found: C, 72.19; H, 9.98; N, 2.51.

6E-Acetoximino-5 β -cholestan-3 β , 5-diol 3-acetate (10) M.p. 157-158.5°C (Et₂O-pentane); [α]_D -0.7 (c, 10.0); IR, cm⁻¹; 3475, 1765, 1735, 1716, 1643, 1217, 1175, 1053; MS, m/z (relative intensity): 457 (M⁺-AcOH, 6.8), 397 (M⁺-2AcOH, 30.4), 369 (M⁺-2AcOH-CO, 60.6), 110 (C₇H₁₀O⁺, 100); Anal.: calcd. for C₃₁H₅₁NO₅: C, 71.92, H, 9.93; N, 2.71; found: C, 71.84, H, 9.83; N, 2.65.

6E-Acetoximino-5β -cholestan-3β, 5-diol 3, 5-diacetate (12) Amorphous; $[^{\alpha}]_{D}$ -43.4 (c, 9.8); IR, cm⁻¹: 1775, 1750, 1647, 1260, 1223, 926; 1 H NMR, δ: 5.18 (H-3α), 3.18 (H-7β), 2.18 (NOAc), 2.07 (C³-OAc), 1.98 (NOAc), 0.88 (H-21), 0.91 (H-19), 0.85 (H-26/27), 0.62 (H-18); MS, m/z (relative intensity): 440 (M⁴-AcO-AcOH, 10.7); 398 (48.1); 397 (100); 110 (C₇H₁₀O⁺,5.2); Anal. calcd. for C₃₃H₅₃NO₆: C, 70.81; H, 9.54; N, 2.50; found: C, 70.69; H, 9.36; N, 2.37.

Highfield ¹R and ¹³C NMR

ACKNOWLEDGEMENTS

Acknowledgement is made to the Fonds der Chemischen Industrie for the support given to this work.

REFERENCES

- 1 J. Frelek and G. Snatzke, in preparation.
- 2 G.E. Hawkes, K. Herwig and J.D. Roberts, J. Org. Chem. 39, 1017 (1974).
- 3 H. Duddeck, unpublished results.
- (a) J.W. Blunt and J.B. Stothers, Org. Magn. Reson.9, 439 (1977); (b) W.B. Smith, Annu. Rep. NMR Spectrosc., ed. by G.A. Webb, Academic Press, New York, 8, 199 (1978); (c) E. Breitmaier and W. Voelter, ¹³C NMR Spectroscopy, 2nd. ed., Verlag Chemie, Weinheim (1978); (d) R.-O. Kalinowski, S. Berger and S. Braun, ¹³C-NMR-Spektroskopie, Thieme, Stuttgart (1984).
- 5 A. Bax, Two-Dimensional Nuclear Magnetic Resonance in Liquids, Reidel, Dordrecht (1982); R. Benn and H. Gunther, Angew. Chem.95, 381 (1983), Angew. Chem. Int. Ed. Engl. 22, 350 (1983); Angew. Chem. Int. Ed. Engl. 22, 350 (1983); A. Bax, Top. Carbon-13 NMR Spectrosc., ed. by G.C. Levy, Wiley, New York 4, 197 (1984)
- 6 H. Duddeck, D. Rosenbaum, M.E.A. Elgamal and M.B.E. Fayez, Magn. Reson. Chem. 24, 999 (1986).
- 7 N.S. Bhacca and D.H. Williams, Applications of NMR Spectroscopy in Organic Chemistry, Holden-Day, San Francisco (1964); R.F. Zurcher, Progr. Nucl. Magn. Reson. Spectrosc., ed. by J.W. Emsley, J. Feeney and L.B. Sutcliffe, Pergamon Press, Oxford, 2, 205 (1967); J.W. ApSimon and H. Beierbeck, Can. J. Chem. 49, 1328 (1971).
- 8 (a) L.D. Hall, J.K.M. Sanders and S. Sukumar, J. Chem. Soc., Chem. Commun. 366 (1980); (b) L.D. Hall and J.K.M. Sanders, J. Chem. Soc., Chem. Commun. 368 (1980); (c) L.D. Hall and J.K.M. Sanders, J. Org. Chem. 46, 1132 (1982); (d) M.W. Barrett, R.D. Farrant, D.N. Kirk, J.D. Mersh, J.K.M. Sanders and W.L. Duax, J. Chem. Soc., Perkin Trans. 2 105 (1982); (e) A.G.J. Sedee, G.M.J. Beijerbergen van Henegouwen, W. Guijt and C.A.G. Haasnoot, J. Chem. Soc., Perkin Trans. 2 1755 (1984); (f) T.C. Wong and G.R. Clark, J. Chem. Soc., Chem. Commun. 1518 (1984); (g) H.-J. Schneider, U. Buchheit, N. Becker, G. Schmidt and U. Siehl, J. Am. Chem. Soc 107, 7027 (1985).
- 9 (a) F.A. Bovey, Nuclear Magnetic Resonance Spectroscopy, Academic Press, New York (1969); (b) H. Gunther, NMR-Spektroskopie, 2nd. ed., Thieme, Stuttgart (1980).
- 10 b. Duddeck, M. Kaiser and D. Brosch, Magn. Reson. Chem. 23, 548 (1985).
- 11 C.M. Shoppee and S.K. Roy, J. Chem. Soc., 3774 (1963).
- 12 C.B. Narayanan and M.S. Parkar, Chem. Ind., 163 (1974).
- 13 M. Meot-Ner, E. Premuzic, S.R. Lipsky and J. McMurray, Steroids 19, 493 (1972).

Ducdeck et al

- Sugimone and Ch.-M. Shea, Synthesis, 229 (1980).
- A. Hassner and C. Heathcock, J. Org. Chem. 29, 1350 (1964). 15
- 16
- J.R. Hanson and E. Premuzic, Tetrahedron, 23 4105 (1967).
 M.S. Ahmad, N.R. Pillai and Z.H. Chaudhry, Aust. J. Chem., 27, 17 1537 (1974).
- M. Onda and K. Takeuchi, Chem. Pharm. Bull., 23, 677 (1975). 18